Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Odyssey Therapeutics, Inc. Common Stock

ODTX

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Last trade $19.40
Day change +$0.035 (+0.18%)
Day range $18.65 – $19.62
Volume 187,899
Market cap $931M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$930.59M
Price / earnings
—
Price / book
2.48×
Price / sales
—
EV / sales
—
EV / EBITDA
-5.85×

Profitability

Earnings per share
-$3.00
Return on assets
-32.89%
Return on equity
-38.35%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
12.94×
Quick ratio
12.94×
Cash ratio
3.09×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$149.23M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ODTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$11.24M$10.51M
Research and development$42.12M$36.23M
Total operating expenses$53.36M$55.47M
Operating income-$53.36M-$55.47M
Interest expense-$12K-$20K
Income before taxes-$53.01M-$52.8M
Income taxes$49K-$8K
Net income-$53.06M-$52.79M
Net income attributable to common shareholders-$53.06M-$52.79M
EBITDA-$52.35M-$54.43M
Basic earnings per share-$1.10-$1.74
Diluted earnings per share-$1.10-$1.74

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.